Finally, the cells were treated with Invitrogen SlowFade Gold anti-fade reagent (Thermo Fisher Scientific, USA)

Finally, the cells were treated with Invitrogen SlowFade Gold anti-fade reagent (Thermo Fisher Scientific, USA). == Measurement of glycoPER and OCR == Sorted Mouse monoclonal to PRKDC nave CD4+T cells were cultured under Treg polarizing conditions as described above and treated with or without butyrate (0.2 mM) for 3 days, harvested, and seeded in 24-well plates coated with 22.4g/mL Corning Cell-Tak Cell and Tissue Adhesive (Biocoat, USA) using a density of 3105cells per well. cytotoxic T-lymphocyte-associated protein 4 on Treg cells, thereby promoting Treg differentiation and their suppressive function in AChR MG. This observed effect of butyrate was blocked using chloroquine, an autophagy inhibitor, suggesting the vital role of butyrate-activated autophagy in Tregs of patients with AChR MG. We Linifanib (ABT-869) propose that gut bacteria Linifanib (ABT-869) derived butyrate has potential therapeutic efficacy against AChR MG by restoring impaired Tregs. == Supplementary Information == The online version contains supplementary material available at 10.1186/s12964-024-01588-9. Keywords:Myasthenia gravis, Treg, Gut microbiota, Butyrate, Autophagy == Background == Myasthenia gravis (MG) is an autoimmune disorder characterized by weakness in the ocular, respiratory, limb, and bulbar muscles [1] that is worsened by activity [2]. Long-term studies have confirmed that muscle weakness in MG is typically caused by autoantibodies against nicotinic acetylcholine receptors (AChRs), muscle-specific tyrosine kinase, lipoprotein receptor-related protein 4, and agrin [36]. Anti-AChR antibodies are detectable in 80-85% of patients with MG [7,8], while other subtypes of antibodies can be detected in only a small percentage of patients with MG. Thus, the presence of anti-AChR antibodies have become one of the significant clinical hallmarks of MG [9]. AChR-specific CD4+T cells (T helper (Th) 1 and Th17 cells) and related cytokines [10,11] are involved in the synthesis of anti-AChR antibodies [12]. Increased numbers of Th1 and Th17 cells stimulate B cells to produce excessive anti-AChR antibodies in patients with AChR MG [1315]. However, the conversation of AChR-specific CD4+T cells with B cells to produce anti-AChR antibodies is usually regulated by regulatory T (Treg) cells. Treg cells maintain immune homeostasis by suppressing excessive immune responses [16]. In AChR MG, Tregs can function as suppressors to inhibit the abnormal over-differentiation of AChR-specific CD4+T cells and related cytokines [17,18], thereby balancing the production of anti-AChR antibodies. Researchers have observed the impaired suppressive function of Tregs in AChR MG, and the proportion of Tregs is lower in patients with AChR MG than in healthy controls [19]. However, the mechanism of Treg dysfunction and reduced Treg cell numbers in AChR MG is not fully comprehended. The gut microbiota play a significant role in the progression of various autoimmune diseases, such as rheumatoid arthritis [20], systemic lupus erythematosus [21], and multiple sclerosis [22]. Previous researches have exhibited that the composition and abundance of gut microbiota in MG are significantly different from healthy controls [23]. Gut microbiota may serve as biomarkers for the diagnosis of MG [23]. Recent studies have confirmed that Linifanib (ABT-869) gut microbiota could potentially affect the host immune responses is Linifanib (ABT-869) usually by directly functioning as antigens or via their metabolites. For example,ClostridiaandRoseburiaare known to promote the numbers of Treg cells as well as contributing to the production of short-chain fatty acids (SCFAs) [24]. SCFAs, including acetic acid, propionic acid, and butyric acid, can activate the differentiation of CD4+T cells [25,26] and CD8+T cells [27]. Moreover, reduced SCFAs levels, especially butyrate, have been observed in patients with MG [28]. However, disturbed gut microbiota as a characteristic of patients with AChR MG has not been reported, and the association between gut microbiota and impaired Tregs in AChR MG is still unknown. In this manuscript, we analyzed the characteristics of gut microbiota in patients with AChR MG, and the serum levels of gut microbiota-derived SCFAs. We further investigated the effects of SCFAs, particularly butyrate, on Tregs in patients with AChR MG. This may provide a potential pathogenic mechanism for MG. == Materials and methods Linifanib (ABT-869) == == Human subjects == 11 healthy controls and 22 patients MG matched in gender and age were recruited. Patients were diagnosed according to the Myasthenia Gravis Foundation.